Bempedoic Acid Improves Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk - report from ACC2023

Prosessor Eliot A. Brinton explains the results of the CLEAR Outcomes trial, the first study to assess whether bempedoic acid could reduce cardiovascular outcomes. The cholesterol-lowering drug bempedoic acid reduced the combined rate of major adverse cardiovascular events by 13%, meeting its primary endpoint in a large study of patients with high cholesterol who were unable to tolerate statins, according to research being presented at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology. Video: https://medicaldigest.org/scientific-contents/interview:bempedoic-acid-improves-cardiovascular-outcomes-statin-intolerant-patients-high-cardiovascular-risk